Pharsight

Lumigan patents expiration

LUMIGAN's oppositions filed in EPO
LUMIGAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278353 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8586630 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8524777 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US9155716 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8338479 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8772338 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8299118 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US9241918 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8309605 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8933120 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

US8933127 ALLERGAN Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 5 months from now)

Lumigan is owned by Allergan.

Lumigan contains Bimatoprost.

Lumigan has a total of 12 drug patents out of which 0 drug patents have expired.

Lumigan was authorised for market use on 31 August, 2010.

Lumigan is available in solution/drops;ophthalmic dosage forms.

Lumigan can be used as a method of lowering intraocular pressure, a method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension, a method of treating a patient with glaucoma or ocular hypertension, reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension, a method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient, method of treating glaucoma or elevated intraocular pressure.

The generics of Lumigan are possible to be released after 13 June, 2027.

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 31 August, 2010

Treatment: A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A me...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage

LUMIGAN family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic